| Literature DB >> 24523749 |
Hadi Adibi1, Mohammad Bagher Majnooni2, Ali Mostafaie3, Kamran Mansouri3, Moslem Mohammadi4.
Abstract
Compounds containing triazene ring structure are cytotoxic agents and clinically used as antitumor alkylating agents. In this study, a series of triazene derivatives holding alkyl and aryl moieties were synthesized and proved to be potent cytotoxic agents in-vitro particularly against eight cancer cell lines (PC3, HT29, Hela, HL60, Jurkat, K562, MCF7, HepG2) and a non-cancerous cell line (HUVEC). The cytotoxic activity was assessed using two methods, LDH assay, and trypan blue exclusion. Some of the triazene derivatives showed cytotoxic activity more than temozolomide (TMZ) as the reference drug. The synthesized triazenes showed marked cytotoxicity effects on all eight cancer cell lines. Among the compounds synthesized, 1,3-bis(2-ethoxyphenyl)triazene C had unique efficacy and selectivity so that it had IC50 between 0.560-3.33 μM on cancer cell lines and 12.61 μM on normal cell line (HUVEC). 1-(4-nitrophenyl)-3-(2-hydroxyethyl)triazene E shows weaker effect on cancer cell lines than the other compounds having IC50 between 3-15.54 μM.Entities:
Keywords: Cancer cell lines; Cytotoxic activity; LDH assay; Triazene derivatives; Trypan blue exclusion
Year: 2013 PMID: 24523749 PMCID: PMC3920694
Source DB: PubMed Journal: Iran J Pharm Res ISSN: 1726-6882 Impact factor: 1.696
Figure 1Structures of dacarbazine and temozolomide used in clinical treatment
Cytotoxic activities of triazene analogs with LDH assay (IC50 in μM).
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|
| A | 1.51 ± 0.26 | 1.12 ± 0.30 | 1.24 ± 0.20 | 2.82 ± 0.49 | 8.87 ± 2.1 | 2.3 ± 0.51 | 2.1 ± 0.70 | 1.2 ± 0.40 | 4.4 ± 1.31 | 85 |
| B | 1.78 ± 0.50 | 1.89 ± 0.78 | 3.29 ± 1.30 | 3.37 ± 1.65 | 4.2 ± 1.40 | 1.36 ± 0.34 | 1.13 ± 0.67 | 1.05 ± 0.98 | 3.22 ± 1.10 | 87 |
| C | 0.59 ± 0.12 | 3.33 ± 1.30 | 0.56 ± 0.20 | 2.55 ± 1.33 | 2.54 ± 1.20 | 2.62 ± 0.96 | 1.66 ± 0.8 | 1.69 ± 1.02 | 12.61 ± 2.80 | 90 |
| D | 1.45 ± 0.32 | 1.49 ± 0.42 | 1.04 ± 0.11 | 2.03 ± 1.05 | 2.39 ± 1.35 | 1.34 ± 0.44 | 1.04 ± 0.38 | 1.44 ± 0.71 | 1.14 ± 0.40 | 88 |
| E | 6.14 ± 1.89 | 4.2 ± 1.20 | 3 ± 1.01 | 8.25 ± 2.20 | 15.54 ± 3.01 | 2.81 ± 0.99 | 9.87 ± 2.08 | 4.5 ± 1.67 | 5.05 ± 1.80 | 89 |
| F | 2.17 ± 0.53 | 1.45 ± 0.65 | 7 ± 2.20 | 2.26 ± 1.52 | 6.85 ± 2.80 | 1.3 ± 0.50 | 1.66 ± 0.49 | 1.61 ± 0.90 | 4.59 ± 1.76 | 92 |
| G | 1.57 ± 0.34 | 3.94 ± 1.45 | 4.13 ± 1.80 | 9.4 ± 2.30 | 4.88 ± 1.50 | 3.4 ± 1.96 | 6.33 ± 2.41 | 5.53 ± 1.44 | 7.43 ± 2.10 | - |
| TMZ | 0.77 ± 0.22 | 2.59 ± 1.30 | 1.39 ± 0.69 | 17.24 ± 3.20 | 8.88 ± 2.2 | 3.54 ± 1.56 | 3.82 ± 1.60 | 2.07 ± 1.34 | 4.85 ± 1.78 | - |
Figure 2The percentage of viability versus concentration by trypan blue exclusion on cancer cell line MCF7 (human breast adenocarcinoma).
Figure 9The percentage of viability versus concentration by trypan blue exclusion on cancer cell line Jurkat (Human Acute T-cell leukemia).
Figure 6The percentage of viability versus concentration by trypan blue exclusion on cancer cell line Hela (Human cervix carcinoma).
Figure 8The percentage of viability versus concentration by trypan blue exclusion on cancer cell line K562 (Human chronic myelogenom leukemia).